#Mutation Detection Kit Market Research Report

[bisresearch0]

Latin America NGS Market - Analysis and Forecast, 2024-2034 | BIS Research

What is Latin America NGS market?  

The Latin America next-generation sequencing (NGS) market refers to the comprehensive application of NGS technologies for clinical diagnostics, translational research across Latin American countries. This market includes instruments, such as sequencers, and consumables, such as reagents, kits, software, and services. 

Next-generation sequencing (NGS) is transforming healthcare by enabling comprehensive genomic analysis for personalized medicine. NGS facilitates the use of targeted medicines, accurate tumor profiling, and the discovery of actionable mutations in oncology. 

What is the market size of the Latin America NGS market? 

In 2024, The Latin America NGS Market was valued at $268.04 million. It is projected to grow at a compound annual growth rate (CAGR) of 8.34%, reaching $597.20 million by 2034.

What are the emerging trends in the Latin America market?

Growing Adoption of Personalized Medicine: The Latin America NGS market is growing rapidly due to its expanding role in oncology and infectious disease research, driven by the rising demand for precision medicine and its critical applications in cancer mutation detection and virological studies such as COVID-19 and HBV.

Increasing Local Production and Infrastructure: Countries in Latin America are investing in local NGS infrastructure by establishing genomics centers and bioinformatics training programs, such as the CABANA model in Mexico, to reduce reliance on international services and enhance regional genomic research capabilities.

Expansion of Genomic Data Accessibility: Efforts to increase the accessibility of genomic data are growing, with partnerships such as Lifebit, Omica.bio, and gen-t in Brazil and Mexico enhancing local data representation in global datasets to support more inclusive and accurate population health research.

What are the main challenges or barriers to NGS adoption in Latin America?

Cost-Effectiveness: The high expense of next-generation sequencing (NGS) testing continues to prevent its broad use in the region, which in turn prevents the Latin America NGS market from expanding, especially in countries with much lower average incomes like Brazil, Mexico, and Argentina. Notwithstanding worldwide cost decreases, issues with affordability still prevent NGS from being fully incorporated into regional healthcare systems.

Lack of Funding and Reimbursement:The region's public healthcare systems lack the funds necessary to build the necessary infrastructure for genetic testing, which forces reliance on expensive private labs and impedes the expansion of the Latin American NGS industry. NGS uptake and sustainability in the region are further limited by the high cost of clinical exome sequencing and low reimbursement rates, especially in the public sector.

Lack of Education, Awareness, and Specialists: One of the main obstacles to the wider adoption of genomic technologies in Brazil is the lack of knowledge among patients and healthcare professionals about these technologies, including whole genome and exome sequencing, as well as a lack of medical education and specialized professionals. The efficient use of these technologies is hampered by this knowledge gap, unclear guidelines, and restricted access to experts.

Get Informed: Explore the Influence of Increasing Investments in The Latin America NGS Market Market – Access Our Sample Report!

Learn more about Healthcare Vertical. Click Here!

Conclusion

The Latin America NGS market is poised for significant growth, driven by increasing demand for personalized medicine, advancements in genomic infrastructure, and expanding research collaborations. Opportunities in fields including growing genetic data, setting up diagnostic centers, and incorporating NGS into healthcare systems present a bright future despite obstacles like exorbitant costs, a lack of funding, and a shortage of skilled workers. The Latin American NGS market is anticipated to play a significant role in the advancement of global healthcare as local genomic capabilities increase and accessibility improves.

[aimarketresearch]

Breast Cancer Liquid Biopsy Market Size, Share, Trends, Growth Opportunities and Competitive Outlook

Breast Cancer Liquid Biopsy Market – Industry Trends and Forecast to 2030

Global Breast Cancer Liquid Biopsy Market, By Product (Consumables and Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, and Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, and Pathology Laboratories) - Industry Trends and Forecast to 2030.

Access Full 350 Pages PDF Report @

**Segments**

- Based on product type, the breast cancer liquid biopsy market can be segmented into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers. Circulating tumor cells (CTCs) segment is expected to witness significant growth due to its ability to detect and monitor cancer progression through the analysis of tumor cells present in the bloodstream. Cell-free DNA (cfDNA) segment is also anticipated to show substantial growth as it offers non-invasive and real-time monitoring of cancer status. The increasing adoption of liquid biopsy for early cancer detection and personalized treatment is driving the growth of this segment in the market.

- In terms of technology, the market can be categorized into polymerase chain reaction (PCR), next-generation sequencing (NGS), immunoassays, and other technologies. The next-generation sequencing (NGS) segment is likely to dominate the market owing to its high sensitivity and specificity in detecting cancer-related mutations. Immunoassays segment is also gaining traction due to its cost-effectiveness and ease of use in detecting specific biomarkers associated with breast cancer. The advancements in technology for liquid biopsy are enhancing the precision and accuracy of cancer diagnosis, propelling market growth.

- On the basis of application, the breast cancer liquid biopsy market is segmented into early cancer screening, treatment monitoring, recurrence monitoring, and others. Treatment monitoring segment is expected to lead the market as liquid biopsy enables real-time monitoring of treatment response and resistance mechanisms in breast cancer patients. Early cancer screening segment is also projected to grow significantly due to the rising emphasis on early detection for better treatment outcomes. The ability of liquid biopsy to track cancer recurrence is further fueling the demand for this technology in the market.

- By end-user, the market is segmented into hospitals, diagnostic laboratories, research centers, and others. Hospitals segment is poised to be the largest consumer of breast cancer liquid biopsy products due to the increasing prevalence of breast cancer cases and the need for advanced diagnostic tools in hospital settings. Diagnostic laboratories are also witnessing substantial growth as they play a crucial role in conducting liquid biopsy tests for breast cancer patients. Research centers are actively involved in developing innovative liquid biopsy technologies, driving market expansion in this segment.

**Market Players**

- Some of the key players in the global breast cancer liquid biopsy market include Guardant Health, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, QIAGEN, Illumina, Inc., Menarini Silicon Biosystems, Cynvenio Biosystems, Inc., and Fluxion Biosciences, Inc. These companies are focusing on strategic collaborations, product launches, and acquisitions to strengthen their market presence and expand their product portfolio in the breast cancer liquid biopsy domain. The competitive landscape of the market is characterized by innovative product offerings and research collaborations to enhance cancer diagnosis and treatment outcomes.

https://www.databridgemarketresearch.com/reports/global-breast-cancer-liquid-biopsy-marketThe breast cancer liquid biopsy market is witnessing significant growth and evolution driven by various factors such as technological advancements, increasing prevalence of breast cancer cases, and the growing emphasis on personalized and early cancer detection and treatment. One of the key trends shaping the market is the shift towards non-invasive and real-time monitoring of cancer status through liquid biopsy techniques. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) are proving to be valuable biomarkers in detecting and monitoring cancer progression, thereby fueling the demand for liquid biopsy in breast cancer diagnosis.

Technological advancements, especially in next-generation sequencing (NGS) and immunoassays, are revolutionizing the landscape of breast cancer liquid biopsy by offering high sensitivity, specificity, and cost-effectiveness in detecting cancer-related mutations and biomarkers. The adoption of liquid biopsy for early cancer screening, treatment monitoring, and recurrence monitoring is reshaping the way breast cancer is diagnosed and managed, leading to better treatment outcomes. This trend is driving market growth and propelling research and development initiatives focused on enhancing the precision and accuracy of cancer diagnosis.

The market segmentation based on end-users highlights the vital role of hospitals, diagnostic laboratories, and research centers in the adoption and development of breast cancer liquid biopsy technologies. Hospitals, being at the forefront of cancer diagnosis and treatment, are the largest consumers of liquid biopsy products due to the increasing burden of breast cancer cases globally. Diagnostic laboratories are crucial in conducting liquid biopsy tests, while research centers are actively engaged in innovating new technologies to enhance cancer diagnosis and treatment outcomes, thereby contributing to the market expansion.

Key players in the global breast cancer liquid biopsy market are focusing on strategic collaborations, product launches, and acquisitions to strengthen their market presence and expand their product portfolios. Companies like Guardant Health, Inc., Thermo Fisher Scientific Inc., and Illumina, Inc. are at the forefront of innovation and are driving the competitive landscape through the development of novel liquid biopsy technologies. The market is characterized by intense competition, leading to continuous advancements in liquid biopsy techniques for breast cancer diagnosis, ultimately benefiting patients through improved detection, monitoring, and treatment strategies.

In conclusion, the breast cancer liquid biopsy market is experiencing significant growth driven by technological advancements, increasing awareness about personalized medicine, and the need for non-invasive and real-time cancer monitoring. The market players are actively engaged in expanding their product offerings and collaborating with key stakeholders to enhance cancer diagnosis and treatment outcomes. With the continuous evolution of liquid biopsy technologies and the growing demand for early cancer detection, the breast cancer liquid biopsy market is poised for sustained growth and innovation in the coming years.**Segments**

- **Global Breast Cancer Liquid Biopsy Market, By Product (Consumables and Kits)** - **Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, and Others)** - **End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, and Pathology Laboratories)**

The global breast cancer liquid biopsy market is witnessing a significant transformation driven by the evolving segmentation based on various factors such as product type, technology, application, and end-users. The product segmentation into consumables and kits offers a comprehensive view of the market dynamics, emphasizing the key components driving the adoption of liquid biopsy techniques in breast cancer diagnosis and monitoring. Circulating biomarkers, including extracellular vesicles, cell-free DNA, ctRNA, circulating tumor cells, cfRNA, and others, play a crucial role in detecting and monitoring cancer progression, thereby shaping the market landscape in terms of biomarker specificity and clinical utility. Furthermore, the segmentation based on end-users highlights the diverse settings where breast cancer liquid biopsy technologies are being utilized, underscoring the pivotal role of laboratories, hospitals, research institutes, and other healthcare facilities in advancing cancer diagnostics and treatment monitoring.

The technological advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), immunoassays, and other technologies are revolutionizing the breast cancer liquid biopsy market by offering enhanced sensitivity, specificity, and cost-effectiveness in detecting cancer-related mutations and biomarkers. The application segmentation, encompassing early cancer screening, treatment monitoring, recurrence monitoring, and other clinical uses, reflects the expanding scope of liquid biopsy techniques in addressing various stages of cancer care. The emphasis on real-time monitoring of cancer status, personalized treatment approaches, and early detection strategies is propelling the adoption of liquid biopsy in breast cancer management, thus reshaping the future of cancer diagnosis and treatment.

The market players, including Guardant Health, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., and other key industry leaders, are actively engaged in strategic collaborations, product launches, and acquisitions to fortify their market presence and broaden their product portfolios in the breast cancer liquid biopsy domain. These companies are driving innovation through research partnerships and technological advancements, shaping the competitive landscape characterized by cutting-edge product offerings and technological breakthroughs. The competitive dynamics of the market are fostering continuous advancements in liquid biopsy techniques for breast cancer diagnosis and treatment, ultimately benefiting patients through improved detection, monitoring, and personalized therapeutic interventions.

In conclusion, the global breast cancer liquid biopsy market is poised for sustained growth and innovation, fueled by technological advancements, increasing awareness about personalized medicine, and the growing demand for non-invasive and real-time cancer monitoring. The segmentation based on product type, technology, application, and end-users provides a holistic view of the market landscape, showcasing the diverse applications and settings where liquid biopsy techniques are revolutionizing breast cancer care. The market players' focus on strategic initiatives and collaborations underscores the industry's commitment to advancing cancer diagnostics and treatment outcomes, paving the way for enhanced precision, personalized therapies, and improved patient outcomes in the evolving landscape of breast cancer management.

The Breast Cancer Liquid Biopsy market research report displays a comprehensive study on production capacity, consumption, import and export for all the major regions across the globe. The target audience considered for this market study mainly consists of Key consulting companies & advisors, Large, medium, and small-sized enterprises, Venture capitalists, Value-added resellers (VARs), Third-party knowledge providers, Investment bankers, and Investors. This global market analysis report is the believable source for gaining the market research that will exponentially accelerate the business growth. The top notch Breast Cancer Liquid Biopsy market report is the best option to acquire a professional in-depth study on the current state for the market.

Table of Contents: Breast Cancer Liquid Biopsy Market

1 Introduction

2 Global Breast Cancer Liquid Biopsy Market Segmentation

3 Executive Summary

4 Premium Insight

5 Market Overview

6 Breast Cancer Liquid Biopsy Market, by Product Type

7 Breast Cancer Liquid Biopsy Market, by Modality

8 Breast Cancer Liquid Biopsy Market, by Type

9 Breast Cancer Liquid Biopsy Market, by Mode

10 Breast Cancer Liquid Biopsy Market, by End User

12 Breast Cancer Liquid Biopsy Market, by Geography

12 Breast Cancer Liquid Biopsy Market, Company Landscape

13 Swot Analysis

14 Company Profiles

Countries Studied:

North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Browse Trending Reports:

Scars Treatment Market Atomic Force Microscope Afm Market Network Slicing Market Hypodermic Needles Market Multivendor Atm Software Market Hexane Market Hemato Oncology Testing Market Onchocerciasis Treatment Market Table Linen Market Fiber Optic Connector In Telecom Market Ion Milling System Market Regular Slotted Container Market Aesthetic Injectables Market Network Management Systems Market Cloud Migration Market Intelligent Humidifiers Market Pediatric Dental Crown Market Twist Dispensing Closures Market Patient Engagement Technology Market Personalized Retail Nutrition And Wellness Market Meter Sockets Market Kraft Pouch Market Industrial Batteries Market Food Grade Nitrogen Gas Market Dental Scaling Units Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com

[walkingghotst]

North America Molecular Diagnostics for Infectious Disease Market Future Plans, and Trends (2022-2030)

The North America molecular diagnostics for infectious disease market was valued at US$ 3,345.15 million in 2022 and is expected to reach US$ 8,419.70 million by 2030; it is estimated to grow at a CAGR of 12.2% from 2022 to 2030.

Molecular Diagnostics for Infectious Diseases in Personalized Medicine Fuels the North America Molecular Diagnostics for Infectious Disease Market

Fueled by continuous advancements in high-throughput technologies, genome research has become increasingly accessible and cost-effective, consequently establishing molecular diagnostics as an ever-more critical asset within clinical laboratories. These sophisticated diagnostic kits and assays deliver rapid and reliable detection outcomes, offering a substantial advantage over traditional methodologies that may involve protracted periods of microbial culturing under controlled laboratory conditions. The progressive movement towards personalized medicine, which emphasizes the customization of therapeutic interventions to align with each patient's unique genetic constitution, lifestyle choices, and environmental exposures, is intrinsically linked to the sophisticated capabilities offered by molecular diagnostics. It facilitates the precise identification of specific biomarkers, genetic mutations, and characteristic patterns of gene expression that are of paramount importance in guiding informed clinical decision-making for optimal patient care.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00029839

North America Molecular Diagnostics for Infectious Disease Strategic Insights

Strategic insights concerning the North America Molecular Diagnostics for Infectious Disease market offer a comprehensive and data-driven examination of the industry's intricate structure, encompassing prevailing market trends, the influence of key industry participants, and the subtle yet significant distinctions between various regional markets within North America. These carefully formulated insights offer actionable and well-substantiated recommendations, empowering readers to strategically differentiate their organizations from their competitive counterparts by proactively identifying previously underexplored market segments or by creatively developing uniquely compelling value propositions for their target customers.

North America Molecular Diagnostics for Infectious Disease Regional Insights

The geographic scope of the North America Molecular Diagnostics for Infectious Disease market specifically delineates the precise territories within which a business actively conducts its operational activities and engages in competitive interactions with other industry players. A deep and nuanced understanding of the diverse array of localized distinctions, such as the wide spectrum of varying consumer preferences (for example, differing demands for specific types of electrical plugs or the desired duration of battery backup), the complexities of the differing economic conditions prevalent across various regions, and the intricacies of the disparate regulatory frameworks implemented by different jurisdictions, is absolutely essential for the effective and efficient tailoring of strategic approaches to precisely address the unique needs and characteristics of individual market segments.

North America Molecular Diagnostics for Infectious Disease Market Segmentation

North America Molecular Diagnostics for Infectious Disease Market Segmentation: By Type

Point-of-Care Testing and Laboratory Testing

North America Molecular Diagnostics for Infectious Disease Market Segmentation: By End User

Human Testing and Vet Testing

North America Molecular Diagnostics for Infectious Disease Market Segmentation: By Application

Detection of Single Pathogen

Detection of Two or More Pathogens

Evaluation of Emerging Novel Infections

Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker

Antimicrobial Resistance Profiling

Patient stratification

Drug Regimen Selection

Toxicity Avoidance

Therapeutic Monitoring

Detection of Predisposition to Disease

North America Molecular Diagnostics for Infectious Disease Market Segmentation: By Disease Type

Sepsis

Prosthetic Joint Infection

Endocarditis

STDs

Mononucleosis

Group A Streptococcus

Sepsis

Prosthetic Joint Infection

Endocarditis

STDs

Chlamydia

Gastrointestinal Infection

Tuberculosis

H1N1 Virus

North America Molecular Diagnostics for Infectious Disease Market Segmentation: By Infection Type

Bacteria

Viral

Fungi

Bacteria

Viral

Fungi

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

[businessmarketreports]

An Overview of Next Generation Sequencers Market: Trends and Insights

The Next-Generation Sequencers (NGS) market is witnessing rapid growth, driven by advancements in sequencing technology, declining costs, and increasing applications across healthcare, research, and agriculture. NGS enables high-throughput DNA sequencing, allowing for a more comprehensive analysis of genomes, transcriptomes, and epigenomes.

Buy Full Report for More Insights on the Next Generation Sequencers Market Forecast Download a Free Sample Report

This market encompasses various components, including instruments, software, and reagents, catering to a wide array of end-users, such as hospitals, research institutes, and biotechnology firms.

1. Market Overview

Market Size and Growth: The NGS market has shown robust growth due to rising demand for genomic analysis in personalized medicine, cancer research, and genetic diagnostics. Increasing adoption in clinical settings, along with advancements in technology, has driven accessibility and expanded market reach.

Regional Trends: North America and Europe currently dominate the market due to high healthcare expenditures, advanced infrastructure, and a significant focus on research and development. Meanwhile, Asia-Pacific is emerging as a promising market due to rising healthcare investments and increasing adoption of genomic medicine.

Key Applications: The major applications for NGS include oncology, infectious disease diagnostics, reproductive health, and hereditary disease screening, along with applications in agriculture and environmental studies.

2. Key Trends in the NGS Market

Declining Sequencing Costs: The costs of sequencing have significantly dropped since the advent of NGS technologies. The "thousand-dollar genome" has become a reality, making genetic testing more affordable and accessible, particularly in research and clinical diagnostics.

Shift Towards Clinical Applications: There is a growing demand for NGS in clinical settings, particularly in oncology for tumor profiling, hereditary disease detection, and pharmacogenomics. Clinical applications are gaining traction due to their potential for precision medicine, helping tailor treatments to individual genetic profiles.

Focus on Cancer Research: Oncology remains a major application area for NGS, as it enables detailed cancer genome analysis, leading to better understanding of mutations and tumor behavior. This technology supports both research and diagnostic applications, fueling demand among pharmaceutical companies and research institutes focused on oncology.

Rise of Liquid Biopsies: NGS is widely used in liquid biopsies, which offer a non-invasive method for cancer detection and monitoring by analyzing cell-free DNA (cfDNA) from blood samples. Liquid biopsies are gaining popularity as they allow real-time monitoring of tumor progression and treatment efficacy, reducing the need for invasive procedures.

Emergence of Long-Read Sequencing: Long-read sequencing technologies, such as those offered by Pacific Biosciences and Oxford Nanopore, are gaining traction due to their ability to provide more comprehensive genomic insights. These technologies are particularly valuable in detecting structural variants and resolving complex genomic regions.

Development of Companion Diagnostics: NGS-based companion diagnostics, used to determine the efficacy and safety of a specific drug for a targeted patient group, are expanding. These diagnostics guide treatment decisions in oncology, particularly for identifying biomarkers associated with certain therapies.

3. Market Segmentation

By Product: The NGS market includes sequencers, software, consumables, and services. Consumables, including reagents and kits, constitute the largest segment due to repeated purchases. However, software solutions are gaining traction as data analysis and interpretation become more complex.

By Technology:

Whole Genome Sequencing (WGS): WGS provides a comprehensive view of the entire genome, making it suitable for research and complex disease studies.

Targeted Sequencing: Targeted sequencing is cost-effective and focuses on specific regions of interest, widely used in oncology and clinical diagnostics.

RNA Sequencing: RNA sequencing enables transcriptome analysis and is valuable in cancer research, gene expression studies, and drug discovery.

Exome Sequencing: Exome sequencing, which targets protein-coding regions, is a more affordable alternative to WGS and is commonly used for diagnosing genetic disorders.

By Application: The NGS market serves several applications, including oncology, infectious disease diagnosis, reproductive health, genetic screening, and forensic analysis. Oncology holds the largest share, while infectious disease applications, particularly in tracking pathogens and outbreaks, are rapidly growing.

By End User: The primary end-users include academic and research institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and government agencies. Hospitals and clinics are showing increasing demand as NGS technology moves from research into clinical diagnostics.

4. Key Drivers and Challenges

Drivers:

Increased Demand for Precision Medicine: The trend toward personalized medicine is a major driver, as NGS allows for tailored treatments based on genetic profiles, improving treatment outcomes.

Growing Investment in Genomic Research: Governments, healthcare institutions, and private companies are heavily investing in genomic research and infrastructure to support NGS applications across various fields.

Expansion of Genetic Screening Programs: Many countries are implementing large-scale genetic screening programs for early detection of genetic disorders and hereditary cancers, boosting demand for NGS.

Challenges:

Data Management and Analysis Complexity: The high volume of data generated by NGS requires advanced bioinformatics solutions for analysis, interpretation, and storage. This creates a need for skilled personnel and sophisticated software.

Regulatory and Ethical Concerns: The regulatory landscape for NGS is evolving, and concerns regarding data privacy and ethical issues are prevalent. Obtaining regulatory approval for clinical NGS applications can be time-consuming.

High Initial Investment: Although sequencing costs have decreased, the initial investment required for NGS platforms and bioinformatics infrastructure remains high, limiting adoption in resource-constrained regions.

5. Competitive Landscape

The NGS market is highly competitive, with established players as well as new entrants focusing on niche applications. Key players are investing in research and development, collaborations, and acquisitions to strengthen their market positions and expand product portfolios.

Illumina, Inc.: Illumina is the market leader, with a dominant position in sequencing instruments and consumables. Its sequencers, including the NovaSeq and NextSeq series, are widely used in research and clinical settings.

Thermo Fisher Scientific, Inc.: Known for its Ion Torrent platform, Thermo Fisher focuses on providing affordable, high-throughput sequencing solutions, with applications ranging from cancer research to infectious disease diagnostics.

Pacific Biosciences: PacBio specializes in long-read sequencing technology, particularly valuable for applications that require high accuracy in structural variant detection. Its Sequel system is popular among researchers in complex genomics.

Oxford Nanopore Technologies: Oxford Nanopore offers portable, real-time sequencing devices like the MinION and PromethION, which are particularly useful for field-based applications and rapid sequencing needs.

BGI Group: Based in China, BGI is a major player in genome sequencing services and provides a range of sequencers tailored for research and clinical applications. Its focus on affordability has helped it gain traction in emerging markets.

Qiagen N.V.: Qiagen provides NGS sample preparation and bioinformatics solutions, with a particular emphasis on clinical diagnostics. Its GeneReader NGS System is aimed at making NGS more accessible in clinical labs.

Agilent Technologies: Agilent offers NGS target enrichment and analysis solutions, focusing on workflows for oncology and hereditary disease testing.

6. Future Outlook

Advancements in Data Analysis Tools: Continued improvements in bioinformatics and artificial intelligence are expected to streamline data interpretation, making NGS more accessible to clinical users and reducing the time required for analysis.

Rise of Multi-Omics Approaches: Multi-omics, which combines genomics with proteomics, transcriptomics, and metabolomics, is expected to enhance the understanding of complex diseases. NGS will play a key role in integrating genomic data with other molecular insights.

Increased Focus on Rare Disease Research: NGS enables the identification of mutations associated with rare genetic disorders, facilitating research and development of targeted therapies. This area is likely to see continued growth, especially as pharmaceutical companies invest in precision medicine.

Expansion of Direct-to-Consumer (DTC) Testing: DTC genetic testing is gaining popularity, and as NGS becomes more affordable, companies may offer more comprehensive and affordable sequencing-based consumer tests.

Development of Point-of-Care Sequencing: Point-of-care NGS devices, offering rapid and portable sequencing capabilities, could find applications in emergency rooms and remote locations, particularly for infectious disease diagnosis.

Conclusion

The NGS market is positioned for substantial growth, driven by its expanding role in clinical diagnostics, advancements in sequencing technology, and increasing affordability. Applications in cancer research, infectious disease detection, and reproductive health are set to grow as the technology becomes more integrated into healthcare systems worldwide. However, challenges such as data complexity and regulatory hurdles will require ongoing innovation in bioinformatics and clear guidelines for clinical use. As technology advances, NGS has the potential to become a routine tool in personalized medicine, facilitating earlier diagnosis, better treatments, and improved patient outcomes across a range of medical fields.

[harshnews]

Protein Engineering Market Size, Share, Trends, Growth Opportunities, Key Drivers and Competitive Outlook

"Global Protein Engineering Market – Industry Trends and Forecast to 2029

Global Protein Engineering Market, By Product (Instruments, Reagents, Service and Software), Technology (Rational Protein Design, Irrational Protein Design), Protein Type (Monoclonal Antibodies, Insulin, Erythropoietin, Interferon, Colony Stimulating Factor, Growth Hormones, Coagulation Factor, Vaccines, Others), End-Users (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

Access Full 350 Pages PDF Report @

**Segments**

- **Product**: The product segment in the protein engineering market includes instruments, reagents, and services. Instruments consist of protein analyzers, Chromatography, Mass Spectrometers, and X-ray Crystallography. Reagents include antibodies, protein labelling, and purification kits. Services include protein sequencing, protein engineering, and protein design. - **Technology**: The technology segment comprises rational protein design, directed evolution, and hybrid technology. Rational protein design involves the use of computational models to design proteins with specific functions. Directed evolution uses iterative rounds of mutation and selection to optimize protein properties. Hybrid technology combines aspects of rational design and directed evolution for protein engineering. - **Application**: Protein engineering finds applications in therapeutics, diagnostics, and industrial processes. In therapeutics, engineered proteins are utilized for drug development, targeted therapy, and personalized medicine. In diagnostics, proteins are used as biomarkers for disease detection and monitoring. In industrial processes, engineered proteins enhance the efficiency of biocatalysts, enzymes, and biosensors.

**Market Players**

- **Thermo Fisher Scientific**: A leading player in the protein engineering market, Thermo Fisher Scientific provides a comprehensive range of instruments, reagents, and services for protein analysis and engineering. The company's advanced technologies and global presence position it as a key player in the market. - **Merck KGaA (EMD Millipore)**: Merck KGaA offers a diverse portfolio of protein engineering tools, including reagents for protein purification, expression systems, and analytics. The company's strong focus on innovation and R&D drives its presence in the protein engineering market. - **Agilent Technologies**: Agilent Technologies is known for its high-quality instruments and solutions for protein analysis and engineering. The company's cutting-edge technologies and broad customer base contribute to its significant market share. - **Bio-Rad Laboratories**: Bio-Rad Laboratories specializes in protein analysis and purification products, serving researchers in academic, biopharmaceutical,Bio-Rad Laboratories has established itself as a prominent player in the protein engineering market due to its extensive range of high-quality protein analysis and purification products. The company's offerings cater to a diverse customer base, including researchers in academic institutions, biopharmaceutical companies, and clinical diagnostics laboratories. Bio-Rad's innovative solutions enable efficient protein characterization, quantification, and purification, essential processes in protein engineering. The company's strong reputation for reliability and accuracy in protein analysis has solidified its position as a trusted provider of tools and reagents for protein research and development.

Bio-Rad Laboratories' commitment to research and development is a key driver of its success in the protein engineering market. The company invests heavily in cutting-edge technology and product innovation to meet the evolving needs of the industry. By continuously introducing new and improved solutions for protein analysis and purification, Bio-Rad stays ahead of the competition and maintains its relevance in the market. This focus on R&D not only enhances the company's product portfolio but also reinforces its reputation as a leader in protein engineering technology.

Furthermore, Bio-Rad Laboratories' strategic partnerships and collaborations with academic institutions, research organizations, and industry players have contributed to its market influence. By fostering strong relationships with key stakeholders in the protein engineering ecosystem, Bio-Rad gains valuable insights into market trends, customer preferences, and emerging technologies. These partnerships also facilitate knowledge exchange, technology transfer, and co-development efforts that drive innovation and enhance Bio-Rad's competitiveness in the market. Leveraging its network of collaborators, Bio-Rad is well-positioned to capitalize on market opportunities and strengthen its market presence in the protein engineering sector.

In addition to its product offerings and research collaborations, Bio-Rad Laboratories' focus on customer satisfaction and support plays a crucial role in its market success. The company's dedication to providing excellent customer service, technical assistance, and training programs ensures that customers receive the necessary guidance and resources to optimize their protein engineering workflows. By prioritizing customer needs and delivering value-added services**Global Protein Engineering Market Analysis**

- The protein engineering market is driven by the increasing demand for novel protein therapeutics and personalized medicine. As advancements in technology enable more precise protein design and engineering, the market is poised for significant growth in the coming years. - The therapeutics segment dominates the protein engineering market, with engineered proteins playing a crucial role in drug development and targeted therapies. The rising prevalence of chronic diseases and the need for more effective treatments drive the demand for protein therapeutics. - Academic research institutes and pharmaceutical & biotechnology companies are the key end-users of protein engineering tools and services. These institutions and organizations invest heavily in protein research to develop innovative therapies and diagnostic solutions, stimulating market growth. - North America and Europe are the leading markets for protein engineering, owing to the presence of established research institutions, biopharmaceutical companies, and technological advancements. Asia-Pacific is expected to witness significant growth due to increasing R&D activities and investments in the healthcare sector. - Key players in the protein engineering market are focusing on strategic partnerships, acquisitions, and product launches to expand their market presence and cater to evolving customer needs. R&D investments and technological innovations remain critical for sustaining competitiveness in the market.

The global protein engineering market is witnessing steady growth driven by advancements in technology, increasing demand for personalized medicine, and the growing focus on protein-based therapeutics. The market is segmented based on products, technologies, protein types, end-users, and geography. In terms of products, instruments, reagents, and

Key points covered in the report: -

The pivotal aspect considered in the global Protein Engineering Market report consists of the major competitors functioning in the global market.

The report includes profiles of companies with prominent positions in the global market.

The sales, corporate strategies and technical capabilities of key manufacturers are also mentioned in the report.

The driving factors for the growth of the global Protein Engineering Market are thoroughly explained along with in-depth descriptions of the industry end users.

The report also elucidates important application segments of the global market to readers/users.

This report performs a SWOT analysis of the market. In the final section, the report recalls the sentiments and perspectives of industry-prepared and trained experts.

The experts also evaluate the export/import policies that might propel the growth of the Global Protein Engineering Market.

The Global Protein Engineering Market report provides valuable information for policymakers, investors, stakeholders, service providers, producers, suppliers, and organizations operating in the industry and looking to purchase this research document.

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Global Protein Engineering Market Landscape

Part 04: Global Protein Engineering Market Sizing

Part 05: Global Protein Engineering Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

The investment made in the study would provide you access to information such as:

Protein Engineering Market [Global – Broken-down into regions]

Regional level split [North America, Europe, Asia Pacific, South America, Middle East & Africa]

Country-wise Market Size Split [of important countries with major market share]

Market Share and Revenue/Sales by leading players

Market Trends – Emerging Technologies/products/start-ups, PESTEL Analysis, SWOT Analysis, Porter’s Five Forces, etc.

Market Size

Market Size by application/industry verticals

Market Projections/Forecast

Browse Trending Reports:

10g Substrate Materials Market Cloud Application Programming Interface Api And Management Platforms And Middleware Market Abscisic Acid Aba Market Benign Mesonephroma Market Cancer Supportive Care Products Market Data Center Interconnect Market Potash Fertilizers Market Private Label Food And Beverage Market Relational Database Market Commercial Lighting Market Ethoxylates Market Eclinical Solutions Market Vaccines Market Spark Plug Market High Visibility Clothing Market Gas Turbine Services Market Dessert Mix Market Lipid Nutrition Market Barrier Films Flexible Electronics Market Nasal Polyposis Drugs Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[industryforecastnews]

Blood Cancer Diagnostics Market To Reach USD 16.04 Billion By 2030

Blood Cancer Diagnostics Market Growth & Trends

The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company’s capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/blood-cancer-diagnostics-market-report

Blood Cancer Diagnostics Market Report Highlights

Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2023. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively

Based on tests, blood tests segment dominated the market and accounted for the largest share in 2023. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection

Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2023. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings

North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies

Asia Pacific is expected to witness the fastest growth over the forecast period from 2024 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Blood Cancer Diagnostics Market Segmentation 

Grand View Research has segmented the global blood cancer diagnostics market based on product, test, end use, and region:

Blood Cancer Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Assay Kits and Reagents

Blood Cancer Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)

Blood Tests

Imaging Tests

Biopsy

Molecular Test

Blood Cancer Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals and Clinics

Diagnostic Labs

Research Institutes

Blood Cancer Diagnostics Regional Outlook (Revenue in USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Sweden

Denmark

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

List Of Key Players in The Blood Cancer Diagnostics Market

Abbott

Illumina

InVivoScribe

Ipsogen (Qiagen)

Asuragen(Bio-Techne)

Danaher Corporation

Sequenta (Adaptive biotechnologies)

SkylineDx

Bio-Rad Laboratories

Alercell

Sophia Genetics

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/blood-cancer-diagnostics-market-report

[bhushans]

Meeting the Needs of a Growing Population: The Evolving Global Liquid Biopsy Market

The global liquid biopsy market is positioned for rapid expansion, with an estimated revenue of USD 1,538.3 million in 2023. According to insights from healthcare domain experts, providers in the liquid biopsy sector can anticipate a robust Compound Annual Growth Rate (CAGR) of 21.7% through 2033. By the end of the forecast period, the market is projected to achieve a valuation of USD 10,938.6 million, reflecting significant growth opportunities within the healthcare industry.

Liquid biopsy, a non-invasive diagnostic technique that detects biomarkers and genetic material in bodily fluids, is revolutionizing cancer diagnosis, monitoring, and treatment. This innovative approach offers several advantages over traditional tissue biopsy, including real-time monitoring, early detection of treatment response or resistance, and the ability to capture tumor heterogeneity

Tumor tissue is currently the gold standard for determining the kind and stage of cancer. Important players are attempting to reduce the current obstacles to its utilization in order to increase its potential applications in the future. The feasibility of liquid biopsy techniques for identifying cancer patients’ genetic profiles has also been shown by a number of research. The studies carefully take into account the reactions in order to track the course of treatment and identify any early warning symptoms of therapeutic resistance.

Request Your Detailed Report Sample With Your Work Email : https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

Liquid biopsies have become more common in recent years due to the desire for more personalized treatment options. Since liquid biopsy is widely available and reasonably priced in many labs, particularly in developing countries, its use is growing in popularity. For instance, several labs offer liquid biopsy tests.

“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.

Key Takeaways from the Liquid Biopsy Market Report

The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.

The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.

In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.

In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.

CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.

By sample type, blood sample type holds prominence in the liquid biopsy market.

Key Developments by Liquid Biopsy Market Players

QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.

Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.

Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).

Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.

Key Companies Profiled:

BIOCEPT, INC.

Qiagen N.V.

Trovagene, Inc

Janssen Global Services, LLC

MDxHealth SA

Natera, Inc

F. Hoffmann-La Roche Ltd

Silicon Biosystems

Pathway Genomics Corporation

Sysmex Corporation

Others

Key Segments Profiled in the Liquid Biopsy Industry Survey:

By Biomarker Type:

CTCs (Circulating Tumour Cells)

ctNA (Circulating tumor Nucleic Acids)

Exosomes

By Sample Type:

Blood Liquid Biopsy

Urine Liquid Biopsy

Other (Plasma, Saliva, CSF) Liquid Biopsy

By Application Type:

Liquid Biopsy for Lung Cancer

Liquid Biopsy for Gastrointestinal Cancer

Liquid Biopsy for Prostate Cancer

Liquid Biopsy for Breast Cancer

Liquid Biopsy for Colorectal Cancer

Liquid Biopsy for Leukemia

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

Japan

Middle East and Africa

[pmi-report111]

GIST Mutation Detection Kit Market   2031; Region Wise Analysis of Top Players in   by its Types and Application

The global "GIST Mutation Detection Kit Market Market" report indicates a consistent and robust growth trend in recent times, projecting a positive trajectory expected to persist until 2031. A significant trend observed in the GIST Mutation Detection Kit Market market is the rising consumer inclination towards environmentally sustainable and eco-friendly products. Furthermore, a notable advancement in this market is the increasing incorporation of technology to elevate both product quality and efficiency. Cutting-edge technologies like artificial intelligence, machine learning, and block chain are actively employed to develop innovative products that outperform traditional options in terms of effectiveness and efficiency. The GIST Mutation Detection Kit Market Market Research Report for 2024 highlights emerging trends, growth opportunities, and potential scenarios envisioned up to the year 2031.

By delving into the latest trends, the report keeps businesses abreast of the dynamic market environment, helping them identify emerging opportunities and navigate potential challenges. The meticulous analysis covers various aspects, offering valuable insights into the historical performance of the market and presenting the current (CAGR) status.

Get a Sample Copy of the Report at: https://www.proficientmarketinsights.com/enquiry/request-sample-pdf/1838

Who are the biggest GIST Mutation Detection Kit Market manufacturers worldwide?

EntroGen (U.S.)

Bio-Rad (U.S.)

AmoyDx (China)

MCLAB (China)

Thermo Fisher Scientific (U.S.)

LCM Genect (Italy)

NimaGen (Netherlands)

Beyotime Biotechnology (China)

Genetron Health (China)

Jiangsu MicroDiag Biomedicine Technology (China)

HELIXGEN (Guangzhou) (China)

Geneseeq (Canada)

ASBACH MEDICAL PRODUCTS GMBH (AMP) (Germany)

Diogene (Swizerland)

3B BlackBio Biotech India (India)

Panagene (South Korea)

Medaysis (U.S.)

The GIST Mutation Detection Kit Market Market is described briefly as follows:

The global GIST Mutation Detection Kit Market Size was USD 409.4 million in 2024 and the market is projected to touch USD 574.2 million by 2031, exhibiting a CAGR of 5.80% during the forecast period.

SWOT Analysis of GIST Mutation Detection Kit Market Market:

A SWOT analysis involves evaluating the strengths, weaknesses, opportunities, and threats of a particular market or business. In the case of the keyword market, we'll be looking at the factors that can impact the industry's performance.

Pestle Analysis of GIST Mutation Detection Kit Market Market:

To better comprehend the market environment, a five-force analysis is performed, which takes into account the bargaining power of the customer, the supplier, the threat of substitutes, the threat of new entrants, and the threat of competition.

Get a Sample Copy of GIST Mutation Detection Kit Market Market Report

What are the Types in GIST Mutation Detection Kit Market Market?

PDGFRA

C-KIT

What are Applications in GIST Mutation Detection Kit Market Market?

Medical

Research

Others

Inquire or Share Your Questions If Any before the Purchasing This Report: https://www.proficientmarketinsights.com/enquiry/queries/1838

Geographical Segmentation:

Geographically, this report is segmented into several key regions, with sales, revenue, market share, and GIST Mutation Detection Kit Market market growth rate in these regions, from 2017 to 2028, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia, and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Some of the key questions answered in this report:

Who are the worldwide key Players of the GIST Mutation Detection Kit Market Industry?

How the opposition goes in what was in store connected with GIST Mutation Detection Kit Market?

Which is the most driving country in the GIST Mutation Detection Kit Market industry?

What are the GIST Mutation Detection Kit Market market valuable open doors and dangers looked by the manufactures in the worldwide GIST Mutation Detection Kit Market Industry?

Which application/end-client or item type might look for gradual development possibilities? What is the portion of the overall industry of each kind and application?

What centered approach and imperatives are holding the GIST Mutation Detection Kit Market market?

What are the various deals, promoting, and dissemination diverts in the worldwide business?

What are the key market patterns influencing the development of the GIST Mutation Detection Kit Market market?

Financial effect on the GIST Mutation Detection Kit Market business and improvement pattern of the GIST Mutation Detection Kit Market business?

Purchase this Report (Price 3200 USD for A Single-User License) at: https://www.proficientmarketinsights.com/purchase/1838

TOC of Global GIST Mutation Detection Kit Market Market Research Report 2023

1 GIST Mutation Detection Kit Market Market Overview

2 Market Competition by Manufacturers

3 GIST Mutation Detection Kit Market Production by Region

4 GIST Mutation Detection Kit Market Consumption by Region

5 Segment by Type

6 Segment by Application

7 Key Companies Profiled

8 Industry Chain and Sales Channels Analysis

9 GIST Mutation Detection Kit Market Market Dynamics

10 Research Finding and Conclusion

11 Methodology and Data Source

[industrynewsupdates]

Future of Cell-based Assays Market: Insights from Industry Experts

The global cell-based assays market size is expected to reach USD 28.56 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs to be supplied robustly to cater to the industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests. Wide applications of these assays in drug development processes are expected to boost the demand. These assays are integral to the drug development process by adopting several technologies, such as CRISPR-Cas9, to allow easy resolution of mutations, knock-ins & knockouts of a specific marker at a precise location on the genome or a given culture of cells.

For instance, Celprogen’s human pancreatic cancer cell line characterization kit is a cell-based ELISA kit that is used for the measurement of the concentration of a protein in cells for the determination of the differentiation status of stem cells, thereby eliminating the need to prepare cell lysates and is widely applicable for drug discovery. On the other hand, key players are undertaking various growth strategies to expand their pipelines, portfolios, and offerings to penetrate the market better. For instance, in July 2022, Mission Bio, Inc., launched assay for the detection of solid tumors through its pharma assay development services to aid the acceleration of the development process of cancer therapeutics by reducing the time & cost to characterize solid tumors.

Moreover, in April 2022, Porvair Sciences exhibited Chromatrap chip kits for epigenetics along with a new range of assay and newly designed cell culture microplates for high throughput screening process, cell growth, and proliferation at the American Association for Cancer Research. Many researchers and clinicians believe that there is a strong necessity for novel cell-based assays for their utility in diagnostics and to devise new therapeutic regimes to effectively combat the growing burden of autoimmune diseases, infectious diseases, and genetic disorders across the globe. Furthermore, the COVID?19 pandemic was substantially disruptive both to the continuance of research activities and the type of assays performed.

Gather more insights about the market drivers, restrains and growth of the Cell-based Assays Market

Cell-based Assays Market Report Highlights

• The assay kits products segment accounted for the largest revenue share in 2024 due to the utilitarian benefits that a test kit could offer to clinicians, researchers, and the normal population.

• Ready-to-use kits and self-administrable diagnostic kits are increasingly trending these days.

• The drug discovery application segment is expected to grow at a lucrative CAGR over the forecast period.

• This is due to a rise in the number of researches for therapeutic drug discovery, an increasing number of FDA approvals, and a rise in demand for novel therapeutic drugs coupled with increasing cases of genetic disorders, cancers, & infectious diseases.

• The academic & research institutes end-use segment is expected to register the fastest CAGR over the forecast period.

• The growth can be attributed to the greater utility of cell-based assays for the diagnosis of cancers, genetic disorders, and infectious diseases.

Cell-based Assays Market Segmentation

Grand View Research has segmented the global cell-based assays market based the products & services, application, end-use, and region:

Cell-based Assays Products & Services Outlook (Revenue, USD Million, 2018 - 2030)

• Reagents

• Assay Kits

o Cell Growth Assays

o Reporter Gene Assays

o Cell Death Assays

o Second Messenger Assays

• Microplates

• Probes & Labels

• Instruments & Software

• Cell Lines

o Primary Cell Lines

o Stem Cell Lines

o Immortalized Cell Lines

Cell-based Assays Application Outlook (Revenue, USD Million, 2018 - 2030)

• Basic Research

• Drug Discovery

• Other Applications

Cell-based Assays End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Contract Research Organizations (CROs)

Cell-based Assays Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Norway

o Denmark

o Sweden

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

o Thailand

• Latin America

o Brazil

o Argentina

o Mexico

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

List of Key Players in the Cell-based Assays Market

• Bio-Rad Laboratories, Inc.

• Corning Incorporated

• Merck KGaA

• Lonza Group AG

• Charles River Laboratories

• Becton, Dickinson and Company (BD)

• Danaher Corporation

• Promega Corporation

• Thermo Fisher Scientific Inc.

• F. Hoffmann-La Roche Ltd. (Roche Holdings AG).

• Perkin Elmer Inc.

Order a free sample PDF of the Cell-based Assays Market Intelligence Study, published by Grand View Research.

[versatile-blogger-1]

Genomics Market Expected To Witness High Growth Driven By Advancements In Technology And Rising Demand For Personalized Medicine

A) Market Overview:

Genomics is the study of genes and their functions, with a focus on understanding the structure, function, evolution, mapping, and editing of genomes. It plays a crucial role in personalized medicine, drug discovery, and the development of precision therapies. The market mainly consists of products such as instruments & consumables, services, and software used in genomic research and diagnostics.

The global Genomics Market is estimated to be valued at US$ 46.2 Bn in 2023 and is expected to exhibit a CAGR of 12.4% over the forecast period 2023-2028, as highlighted in a new report published by Coherent Market Insights.

B) Market Dynamics:

The global Genomics Market is driven by two major factors. Firstly, advancements in technology have revolutionized genomics research and diagnostics. The development of Next-Generation Sequencing (NGS) technologies and its applications in various genomic studies have significantly contributed to market growth. NGS enables faster and cost-effective sequencing of DNA, RNA, and proteins, thereby facilitating a deeper understanding of diseases at a molecular level.

Secondly, there is a rising demand for personalized medicine, which utilizes genomic information to tailor medical treatments to individual patients. The increasing prevalence of chronic diseases such as cancer and genetic disorders has created a need for more targeted therapies. Genomic testing enables the identification of specific genetic mutations associated with these diseases, allowing for personalized treatment plans.

C) Market Key Trends:

One key trend observed in the Genomics Market is the growing adoption of direct-to-consumer genetic testing. Companies such as 23andMe provide consumers with the opportunity to access their genetic information through at-home testing kits. This trend has gained popularity due to increased consumer awareness and curiosity about their DNA and ancestry.

For example, 23andMe offers ancestry reports, health predisposition reports, and carrier status reports, providing individuals with insights into their genetic background and potential health risks. This trend is expected to continue, as more people are interested in exploring their genetic information for various purposes.

D) SWOT Analysis:

Strength:

1. Advancements in technology - Continued advancements in genomic technologies such as NGS drive the market's growth.

2. Increasing demand for personalized medicine - The rising prevalence of chronic diseases and genetic disorders fuels the adoption of genomic approaches in clinical decision-making.

Weakness:

1. High costs associated with genomic testing - The cost of genomic tests and sequencing technologies may limit their accessibility, hindering market growth.

2. Regulatory challenges - Stringent regulations regarding the use and sharing of genetic data pose challenges for the market expansion.

Opportunity:

1. Growing applications in non-invasive prenatal testing - Genomics has the potential to revolutionize prenatal care by enabling non-invasive detection of fetal genetic abnormalities.

2. Expanding use of genomics in agriculture - The agricultural sector can benefit from genomics-based technologies for crop improvement and disease resistance.

Threats:

1. Ethical and privacy concerns - The collection and utilization of genetic data raise ethical questions and privacy concerns among individuals and regulatory bodies.

2. Lack of awareness and limited infrastructure - Limited awareness about genomics and inadequate infrastructure in certain regions can hinder market growth.

E) Key Takeaways:

- The global genomics market is expected to witness high growth, exhibiting a CAGR of 12.4% over the forecast period, driven by advancements in technology and rising demand for personalized medicine.

- North America is currently the largest market for genomics, owing to the presence of well-established healthcare infrastructure, increased funding for genomics research, and a growing consumer base for direct-to-consumer genetic testing.

- Key players operating in the global genomics market include Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, Illumina, Pacific Biosciences, Oxford Nanopore Technologies, 23andMe, Foundation Medicine, Hoffmann-La Roche Ltd., and Myriad Genetics Inc. These players focus on product development, partnerships, and acquisitions to maintain their market position and enhance their product offerings.

[excellreports-blog]

Mutation Detection Kit Market: New Business Opportunities & Investment Research Report 2014-2024

Mutation Detection Kit Market: New Business Opportunities & Investment Research Report 2014-2024

Excell Reports include new market research report “Mutation Detection Kit Market” to its huge collection of research reports at the global and regional level. This report presents the worldwide Mutation Detection Kit market size (value, Capacity, production and consumption), splits the breakdown (data status 2014-2019 and forecast to 2024), by manufacturers, region, type and application. The…

[harshnews]

Acute Myeloid Testing Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis

"Global Acute Myeloid Testing Market - Industry Trends and Forecast to 2029

Global Acute Myeloid Testing Market, By Biomarker Type (Genetic AML Biomarker, Epigenetic AML Biomarker, Proteomic AML Biomarker), Product and Service (Services, Assay Kits), Technology (PCR, IHC, NGS, Cytogenetics, Others), End User (Clinical Laboratories, Hospitals, Academic and Research Institutes, Cancer Diagnostic Institutes, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Access Full 350 Pages PDF Report @

**Segments**

- **Type of Testing**: The acute myeloid testing market can be segmented based on the type of testing into molecular testing and immunophenotyping. Molecular testing involves the analysis of genetic mutations and abnormalities in the DNA of AML cells, aiding in the diagnosis and treatment of the disease. Immunophenotyping, on the other hand, enables the identification of specific proteins on the surface of AML cells, allowing for a more precise understanding of the disease progression.

- **End-User**: The market can also be segmented by end-users, including hospitals and diagnostic laboratories where acute myeloid testing is conducted. Hospitals often have dedicated oncology departments equipped with the necessary infrastructure for diagnosing and treating AML patients. Diagnostic laboratories, on the other hand, specialize in conducting various tests and analyses to assist healthcare professionals in identifying and managing AML cases.

- **Region**: Geographically, the acute myeloid testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Each region has unique characteristics in terms of healthcare infrastructure, regulatory environment, and the prevalence of AML, which can influence the demand for testing services and technologies.

**Market Players**

- **Abbott Laboratories**: Abbott offers a range of diagnostic solutions for oncology, including tests for the detection and monitoring of acute myeloid leukemia. The company's commitment to innovation and quality has solidified its position as a key player in the acute myeloid testing market.

- **F. Hoffmann-La Roche Ltd**: Roche is a leading biotechnology company that provides cutting-edge diagnostic tools and methodologies for the detection and monitoring of various cancers, including AML. The company's strong focus on research and development has resulted in the introduction of advanced testing technologies for improved patient outcomes.

- **Sysmex Corporation**: Sysmex specializes in the development of automated hematology analyzers and diagnostic systems for blood-related disorders, including acute myeloidAbbott Laboratories, F. Hoffmann-La Roche Ltd, and Sysmex Corporation are prominent players in the acute myeloid testing market, each contributing significantly to the advancement of diagnostic solutions for AML. Abbott Laboratories, with its wide range of diagnostic solutions for oncology, has established itself as a key player in the market. The company's focus on innovation and quality has enabled it to provide reliable tests for the detection and monitoring of AML, catering to the diverse needs of healthcare providers and patients.

F. Hoffmann-La Roche Ltd, a leading biotechnology company, has made significant strides in the development of cutting-edge diagnostic tools for various cancers, including AML. Roche's strong emphasis on research and development has led to the introduction of advanced testing methodologies that enhance the accuracy and efficiency of AML diagnosis and monitoring. By leveraging its expertise in biotechnology, Roche continues to drive innovation in the acute myeloid testing market, ultimately improving patient outcomes and healthcare practices.

Sysmex Corporation's specialization in automated hematology analyzers and diagnostic systems for blood-related disorders, including AML, positions the company as a key player in the market. Sysmex's commitment to providing state-of-the-art solutions for AML testing underscores its dedication to advancing healthcare practices and improving patient care. By offering innovative diagnostic systems that deliver precise and reliable results, Sysmex plays a vital role in facilitating the early detection and effective management of AML cases, ultimately contributing to better treatment outcomes for patients.

As the acute myeloid testing market continues to evolve, these market players are expected to maintain their competitive edge through ongoing research and development efforts, strategic partnerships, and investments in new technologies. By staying at the forefront of innovation and continually adapting to the changing healthcare landscape, Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Sysmex Corporation are well-positioned to meet the growing demand for advanced diagnostic solutions in the diagnosis and management of acute myeloid leukemia.**Global Acute Myeloid Testing Market Analysis**

- **Segments**

The global acute myeloid testing market can be segmented based on various factors such as the type of testing, end-users, and regions. When considering the type of testing, molecular testing and immunophenotyping play a crucial role in diagnosing and treating AML effectively. Molecular testing helps in analyzing genetic mutations, while immunophenotyping aids in identifying specific proteins on the surface of AML cells for a more precise understanding of the disease. In terms of end-users, hospitals and diagnostic laboratories are key players in conducting acute myeloid testing, as they have the necessary infrastructure and expertise to diagnose and manage AML cases. Geographically, the market can be segmented into regions like North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, each with its unique characteristics that influence the demand for testing services and technologies.

- **Market Players**

Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Sysmex Corporation are prominent market players in the acute myeloid testing segment. Abbott's commitment to innovation and quality in providing diagnostic solutions for oncology has solidified its position in the market. Roche's focus on research and development has led to the introduction of advanced testing technologies for improved patient outcomes in detecting and monitoring AML. Sysmex's specialization in automated hematology analyzers and diagnostic systems for blood-related disorders positions it as a key player in the market,

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Acute Myeloid Testing Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

How the Report Aids Your Business Discretion?

This section of this Market report highlights some of the most relevant factors and growth enablers that collectively ensure a high-end growth spurt

The report unravels details on pronounced share assessments across both country-wise as well as region-based segments

A leading synopsis of market share analysis of dynamic players inclusive of high-end industry veterans

New player entry analysis and their scope of new business models

The report includes strategic recommendations for new business veterans as well as established players seeking novel growth avenues

A detailed consultation services based on historical as well as current timelines to ensure feasible forecast predictions

A thorough evaluation and detailed study of various segments as well as sub-segments across regional and country-specific developments

Details on market estimations, market size, dimensions

A review of market competitors, their high-end product and service portfolios, dynamic trends, as well as technological advances that portray high end growth in this Market

The Report Can Answer the Following Questions:

Who are the global key players of Acute Myeloid Testing industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?

What are the types and applications of Acute Myeloid Testing ? What is the market share of each type and application?

What are the upstream raw materials and manufacturing equipment of Acute Myeloid Testing ? What is the manufacturing process of Acute Myeloid Testing ?

Economic impact on Acute Myeloid Testing industry and development trend of Acute Myeloid Testing industry.

What are the key factors driving the global Acute Myeloid Testing industry?

What are the key market trends impacting the growth of the Acute Myeloid Testing market?

What are the Acute Myeloid Testing market challenges to market growth?

What are the Acute Myeloid Testing market opportunities and threats faced by the vendors in the global Acute Myeloid Testing market?

Browse Trending Reports:

12g Substrate Materials Market Cloud Application Programming Interface Api And Management Platforms And Middleware Market Abscisic Acid Aba Market Benign Mesonephroma Market Cancer Supportive Care Products Market Data Center Interconnect Market Potash Fertilizers Market Private Label Food And Beverage Market Relational Database Market Commercial Lighting Market Ethoxylates Market Eclinical Solutions Market Vaccines Market Spark Plug Market High Visibility Clothing Market Gas Turbine Services Market Dessert Mix Market Lipid Nutrition Market Barrier Films Flexible Electronics Market Nasal Polyposis Drugs Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[research--blog]

Autoimmune Disease Diagnostics Market Worth $7.53 Billion by 2029

According to a new market research report titled, ‘Autoimmune Disease Diagnostics Market by Product (Reagents, Kits, Assays, Instruments), Test Type (ANA, CRP, ESR, Rheumatoid Factor, Routine Test), Disease Type (Systemic, Localized), End User (Hospital, Diagnostic Lab, Research) – Global Forecast to 2029,’ published by Meticulous Research®, the autoimmune disease diagnostics market is expected to reach $7.53 billion by 2029, at a CAGR of 6.5% from 2022 to 2029.

Download Free Report Sample Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5405

Autoimmune diseases occur when the immune system attacks healthy cells and tissues. The trigger to these attacks can be genetic mutations, microorganisms, viruses, drugs, and environmental factors. The early diagnosis of these autoimmune diseases is necessary for an effective course of treatment or management. Autoimmune diseases can be systemic, affecting multiple organs or systems, or specific, affecting a single organ. Several tests such as western blot, antinuclear antibody, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor, immunoassays, routine blood tests, immunohistochemistry (IHC), and flow cytometry are used for diagnosing autoimmune diseases.

Increasing Prevalence of Autoimmune Diseases Driving the Growth of Autoimmune Disease Diagnostics market

There are more than 80 autoimmune diseases in which the immune system of a patient attacks its own body. The tests for autoimmune prove crucial for the early detection of these diseases. The early diagnosis of autoimmune diseases is also crucial to reduce the financial burden. For instance, according to the American Autoimmune Related Disease Association, around 50 million people in the U.S. suffer from autoimmune diseases and incur USD 86 billion per year in managing their conditions. Autoimmune disease testing is expected to increase due to the increasing prevalence of these diseases. For instance, according to the Lancet Diabetes & Endocrinology, in 2021, around 8.4 million people were affected with type-1 diabetes (one of the most common autoimmune diseases) globally. This number is estimated to increase to 13.5–17.4 million people by 2040. Additionally, around 4% of the global population suffers from one or more autoimmune diseases.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5405

The autoimmune disease diagnostics market is segmented based on Product Category (Reagents, Assays, & Kits and Instruments), Test Type (Antinuclear Antibodies (ANA), Western Blot, Immunoassays, C-reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR)), Rheumatoid Factor, Immunoglobulins, Routine Blood Tests, Immunohistochemistry (IHC), Flow Cytometry, and Other Test Types), Disease Type (Systemic Autoimmune Diseases and Organ-specific Autoimmune Diseases), End Users (Hospitals & Clinics, Diagnostics Laboratories, Academic & Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa). The study also evaluates industry competitors and analyzes the market at the global and regional levels.

Based on the product category, the reagents, kits, and assays segment is slated to register the higher CAGR during the forecast period. The frequent use of reagents for diagnosing diseases and growing awareness and testing capabilities are the major factors driving the growth of this segment.

Based on test type, the antinuclear antibody test segment is slated to register the fastest growth rate during the forecast period. The antibody responsible for autoimmune diseases are formed in the blood much earlier than the onset of the actual disease in an individual; this enables the early diagnosis of the disease, which helps to reduce morbidity and mortality due to the disease. The antinuclear antibodies test is simple and has higher accuracy than other tests. Therefore, the increasing prevalence of autoimmune diseases, the need for early disease diagnosis, and the ease of use and low turnaround time of ANA test drive the segment’s growth.

Quick Buy – Autoimmune Disease Diagnostics Market- Global Opportunity Analysis And Industry Forecast (2022-2029), Research Report: https://www.meticulousresearch.com/Checkout/84306372

Based on disease type, the systemic segment is slated to register the highest CAGR during the forecast period. Systemic autoimmune diseases affect multiple organs or systems. The rising prevalence of systemic autoimmune diseases has led companies operating in the autoimmune disease diagnostics market to launch tests for diagnosing systemic autoimmune diseases. For instance, in June 2022, Thermo Fisher Scientific Inc. (U.S.) launched EliA RNA Pol III and EliA Rib-P tests cleared by the U.S. FDA. These tests are used to diagnose Systemic Sclerosis (SSS) and Systemic Lupus Erythematosus (SLE). Thus, the increasing number of companies launching tests for systemic autoimmune diseases drives this segment’s growth.

Based on end user, in 2022, the hospitals & clinics segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the high adoption rate of testing technologies by hospitals and the rising expansion of existing testing capabilities to provide cost- and time-efficient tests.

Based on geography, in 2022, North America is expected to account for the largest share of the autoimmune disease diagnostics market, followed by Europe and Asia-Pacific. North America’s major market share is attributed to factors such as high healthcare expenditure, high prevalence of autoimmune diseases, increased awareness among patients regarding autoimmune diseases, and increased funding and investments towards R&D of autoimmune diseases.

The report includes an extensive assessment of product portfolios, geography, and key growth strategies adopted by leading market participants between 2020 and 2022.

Some of the key players operating in the autoimmune disease diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Myriad Genetics, Inc. (U.S.), EUROIMMUN Medizinische Labordiagnostika AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.).

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/autoimmune-disease-diagnostics-market-5405

Scope of the Report

Autoimmune Disease Diagnostics Market, by Product Type

Reagents, Assays, and Kits

Instruments

Autoimmune Disease Diagnostics market, by Test Type

Antinuclear Antibodies (ANA) Test

Rheumatoid Factor Test

Immunoglobulins Test

Routine Blood Tests

C-reactive Protein (CRP) Test

Erythrocyte Sedimentation Rate (ESR) Test

Other Test Types

Note: Other test types include Anti-double stranded DNA, Extractable nuclear antigen, Anti-signal recognition particle tests, Ferritin, and Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibodies.

Autoimmune Disease Diagnostics Market, by Disease Type

Systemic Autoimmune Diseases

Organ-specific Autoimmune Diseases

Autoimmune Disease Diagnostics market, by End User

Hospitals & Clinics

Diagnostic Laboratories

Academic & Research Institutes

Autoimmune Disease Diagnostics Market, by Geography

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe (RoE)

Asia-Pacific (APAC)

Japan

China

India

Rest of APAC (RoAPAC)

Latin America (LATAM)

Brazil

Mexico

Rest of Latin America (RoLATAM)

Middle East & Africa

Download Free Report Sample Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5405

[sanpdr1994]

Oncology Blood Testing Market Size, Share, Scope, New Trends, Feasibility Status, Global Trend, Key Players Analysis and Solution Forecast by 2032

The Oncology Blood Testing Market is projected to be worth US$ 3,851.7 million in 2022 and to grow to US$ 18,278.2 million by 2032. During the forecast period, the market is expected to experience tremendous growth at a CAGR of 15.2%.

Oncology Blood Testing: Market Insights

Oncology blood testing is a revolutionary diagnostic technique to detect cancer in early stages. For early detection of cancer, liquid biopsies have become a popular diagnostic tool. Unlike conventional invasive biopsies, liquid biopsies involve blood drawn from the body of suspected patient and is less invasive as compared to the conventional biopsies.  As cancer is a life-threatening, it has to be diagnosed in time and proper treatment should be given in order to be treated. A wide range of oncology blood tests are available in the market to screen cancerous cells in the blood. Some major types of blood tests for detection of cancer includes complete blood count test, blood protein test, tumor marker test, CTC – based test, non-invasive prenatal test, liquid biopsy assays, and exom-based liquid biopsy and thereby contribute majorly to the revenue generation in oncology blood testing market.

Download the sample copy of Report with table of contents and Figures @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6449

Also, oncology blood testing find vast applications in early stage diagnosis of various life-threatening cancers including lung cancer, breast cancer, colon cancer, ovarian cancer and others. The latest research and advancements in human genome sequencing has enabled researchers to diagnose the genetic mutations of distinct cancers. The advanced human genome sequencing with the ability to detect cancerous cells in the blood volume is anticipated to generate large revenues in the oncology blood testing market. The liquid biopsies are done commercially but on a limited basis to detect and treat Stage III or Stage IV cancers. A large number of liquid biopsy tests are currently under clinical trials and would be commercialized soon in the coming years, fuelling the revenue growth in global oncology blood testing market. However, based on the end users, these oncology blood tests are performed largely in hospitals, diagnostic laboratories and specialty clinics.

Oncology Blood Testing: Market Dynamics

Increasing capability of early detection of cancer via oncology blood tests that enables instant treatment decisions, growing prevalence of cancer among people over the globe, increasing production of oncology blood testing assays and kits with capability of being efficient diagnostic tool for cancer detection in blood are some of the major factors expected to drive the growth of oncology blood testing market. Introduction of rapid and technologically advanced liquid biopsy assay, growing awareness about less invasive blood diagnostic tests and increased expenditure in oncology blood screening R&D activities is further propelling the growth of oncology blood testing market. Also, rise in demand for oncology blood testing in the hospitals and diagnostic laboratories is also expected to drive the growth of market. However, large number of diagnostic tools to detect cancer using blood sample are still under development and clinical trial stage, and are not available commercially, thereby restraining the oncology blood testing market growth.

Oncology Blood Testing Market: Segmentation

The global oncology blood testing market is segmented by test type, application and end user.

Oncology Blood Testing Market: Overview

Based on test type, liquid biopsies are most commonly used methods for oncology blood testing in the oncology blood testing market owing to the rapid and accurate results obtained from these tests performed. Liquid biopsy is performed to detect cancer at an early stage as it is capable of detecting cancer-related DNA and proteins present in the blood. The diagnostic labs segment in end user is expected to register largest revenue shares in oncology blood testing market owing to the increased entry of outpatient samples for early diagnosis of cancer, thereby fueling the oncology blood testing market across the globe.

Oncology Blood Testing Market: Region-wise Outlook

On the basis of geography, global Oncology Blood testing market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is projected to hold largest shares in the global oncology blood testing market primarily due to growing population of cancer patients in the region that necessitates need to meet high demand for advanced diagnostic technologies to prevent, diagnose and treat cancer.

North America is followed by Europe which registers second largest shares in global oncology blood testing market worldwide owing to the easy regulatory approval for in vitro cancer diagnostics in Europe. However, Asia Pacific is expected to experience a robust growth over the forecast period in global oncology blood testing market.

Oncology Blood Testing Market: Key Players

Some of the key players present in global Oncology Blood testing market are Guardant Health Inc., Trovagene Inc., Genomic Health Inc., Foundation Medicine Inc., Exosome Diagnostics, Pathway Genomics Corporation and others.

[sanyuktak]

Thyroid Cancer Market Analysis Insights by Latest Trends, Future Growth, Revenue and Demand

Thyroids are situated in the lower front of the neck. The structure of the thyroid is like a butterfly. Thyroids work as a control metabolism that releases hormones all over the body. These hormones play a very important role in the functioning of the body. Thyroid cancer evolves when the cells go through mutation. When the abnormal cells increase in the thyroid, it can lead to a tumor in the thyroid. The treatment of thyroid cancer is possible if it is diagnosed at an early stage.

Request for Sample Report@ https://www.alliedmarketresearch.com/request-sample/10679

Researchers have differentiated thyroid cancer in four different types:

Papillary thyroid cancer

Follicular thyroid cancer

Medullary cancer

Anaplastic thyroid cancer

The symptoms observed in the earlier stages of thyroid cancer are:

Issues in swallowing

Pain in the throat and neck

Cough

Neck lump

Changes in the voice or hoarseness

Purchase Inquiry@ https://www.alliedmarketresearch.com/purchase-enquiry/10679

There has been a significant rise in the frequency of thyroid cancer; growing prominence after the early diagnosis which later helps in the treatment of thyroid cancer are the factors propelling the growth of the thyroid market. Although thyroid cancer is a very uncommon cancer, there has been a significant rise in the incidences reported due to the advances and the upgrades in the technology in the plastic few years.

There has also been a rise in the initiatives taken by the government and rise in the investment and funding for the R & D activities which are also propelling the growth of the thyroid cancer market.

COVID-19 Scenario Analysis:

At the early phase of the COVID-19 pandemic, there was no availability of specific diagnostic tests to detect the disease in patients. Alternative diagnostic tests were used initially but were not much effective. This unavailability of specific COVID-19 diagnostic tests presented lucrative opportunities for diagnostic manufacturers to introduce their COVID-19 diagnostic kits. Many leading players as well as some start-ups from various countries utilized this opportunity and introduced COVID-19 diagnostics kits into local as well as global markets. These players achieved edge over other diagnostics players capitalizing the opportunity from demand for COVID-19 diagnostic tests, which, in turn, helps them in maintaining their revenues in such a crisis.

Key Market Players

Abbott

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific, Inc

Siemens Healthcare GmbH

Bio-Rad Laboratories, Inc

General Electri

Koninklijke Philips N.V

Toshiba Corporation

Agilent Technologies, Inc.

Illumina, Inc.